Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON
2023-507503-62-00Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) comparing GSK4532990 with Placebo (2 arms). Primary endpoints: Histological fibrosis improvement without worsening of NASH at 52 weeks and NASH resolution without worsening of fibrosis at 52 weeks. Started Mar 2023; status: completed.
02
Drugs
GSK4532990
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2023-507503-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507503-62-00.